Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
98.1 EUR | +0.62% | +3.70% | -4.20% |
Apr. 30 | Vetoquinol: down after sales update | CF |
Apr. 29 | Vetoquinol SA Reports Sales Results for the First Quarter of Fiscal 2024 | CI |
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company is not the most generous with respect to shareholders' compensation.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.20% | 1.25B | - | ||
-14.35% | 77.13B | B+ | ||
+14.09% | 8.4B | B- | ||
+27.62% | 3.79B | B- | ||
-0.70% | 3.22B | B- | ||
+14.70% | 1.64B | - | ||
-10.12% | 1.5B | B | ||
-22.60% | 1.3B | C- | ||
-10.26% | 1.18B | - | ||
+5.06% | 1.1B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- VETO Stock
- Ratings Vetoquinol SA